KRAS genotyping as biomarker in colorectal cancer: A comparison of three commercial kits on histologic material

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5251-5256

  Cavallini, Aldo ^a   Valentini, Anna Maria ^a   Lippolis, Catia ^a   Campanella, Daniela ^a   Guerra, Vito ^a   Caruso, Maria Lucia ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Diagnostic kit; Kras mutation; Metastatic colorectal carcinoma

Indexed keywords

K RAS PROTEIN; REAGENT;

ARTICLE; CODON; COLORECTAL CANCER; DIAGNOSTIC KIT; DNA FRAGMENTATION; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

CODON; COLORECTAL NEOPLASMS; DNA, NEOPLASM; GENES, RAS; GENOTYPE; HUMANS; MUTATION; NEOPLASM METASTASIS; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REAGENT STRIPS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 78751564399     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. van Cutsem E, Kohne C-H, Hitre E, Zaluski J, Chien CRC, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J and Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009.
2. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD and Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
3. Neumann J, Zeindl-Eberhart E, Kirchner T and Jung A: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205: 858-862, 2009.
4. van Krieken JHJM , Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, QuirkeP, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G and Ensari A: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programme. Virchow Arch 453: 417-431, 2008.
5. Zsikla V, Baumann M and Cathomas G: Effect of buffered formalin on amplification of DNA from paraffin wax-embedded small biopsies using real-time PCR. J Clin Pathol 57: 654-656, 2004. (Pubitemid 38725772)
6. Gilbert MTP, Haselkorn T, Bunce M, Sanchez JJ, Lucas SB, Jewell LD, van Marck E and Worobey M: The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when? PLoS ONE 6: e537, 2007
7. Serth J, Kuczyk MA, Paeslack U, Lichtinghagen R and Jonas U: Quantitation of DNA extracted after micropreparation of cells from frozen and formalin-fixed tissue sections. Am J Pathol 156: 1189-1196,2000. (Pubitemid 30659997)
8. Jackson DP, Lewis FA, Taylor GR, Boylston AW and Quirke P: Tissue extraction of DNA and RNA and analysis by the polymerase chain reaction. J Clin Pathol 43: 499-504, 1990. (Pubitemid 20173188)
9. Zsikla V, Baumann M and Cathomas G: Effect of buffered formalin on amplification of DNA from paraffin wax-embedded small biopsies using real-time PCR. J Clin Pathol 57: 654-656, 2004. (Pubitemid 38725772)
10. Juan T, Suggs S, Wolf M, Sarosi I, Freeman D, Oliner K, Bakkar A and Patterson SD: A comparability study of 4 commercial KRAS tests. American Association for Cancer Research (AACR) Annual Meeting, Abstract 1811 April 1216,2008.
11. Oliner K, Juan T, Suggs S, Wolf M, Sarosi I, Freeman DJ, Gyuris T, Baron W, Bakker A, Parker A and Patterson SD: A comparability of 5 commercial tests. Diagn Path 5: 23, 2010.
12. Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, Fountzilas G and Karkavelas G: Targeted KRAS mutation assessment on patient tumor histologic material in real-time diagnostics. PLoS ONE 4: e7746, 2009.
13. Caruso ML, Cavallini A, Valentini AM, Campanella D, Armentano R and Pirrelli M: KRAS genotyping on formalinfixed, paraffin- embedded (FFPE) colorectal cancer tissue in diagnostic routine: comparison of methods. Virchow Arch 457: 225-226,2010.
14. Angulo B, García-García E, Martínez R, Suárez-Gauthier A, Conde E, Hidalgo M and López-Ríos F: A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 12: 292-299, 2010.
15. Zavodna K, Konecny M, Krivulcik T, Spanik S, Behulova R, Vizvaryova M, Weismanova E, Galbavy S and Kausitz: Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients. Neoplasma 56: 275-278, 2009.
16. Cross J: DxS Ltd. Pharmacogenomics 9: 463-467, 2008.
17. Ausch C, Buxhofer-Ausch V, Oberkanins C, Holzer B, MinaiPour M, Jahn S, Dandachi N, Zeillinger R and Kriegshauser G: Sensitive detection of KRAS mutations in archived formalinfixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn 11: 508-513, 2009.
18. Kimura K, Nagasaka T, Hoshizima N, Sasamoto H, Notohara K, Takeda M, Kominami K, Lishii T, Tanaka N and Matsubara NJ: No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations. Int Med Res 35: 450-457, 2007. (Pubitemid 47261106)
19. Greer CE, Petersen SL, Kiviat NB and Manos MM: PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol 95: 117-124, 1991.
20. Roberts L, Bowers J, Sensinger K, Lisowski A, Getts R and Anderson MG: Identification of methods for use of formalinfixed, paraffin-embedded tissue samples in RNA expression profiling. Genomics 94: 341-348, 2009.
21. Chen C-Y, Shiesh S-C and Wu S-J: Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis. Clin Chem 50:481-489, 2004.
22. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, SeboltLeopold J, Shannon KM, Settleman J, Giovannini M and Jack T: Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40: 600-608, 2008.
23. Winder T, Mundlein A, Rhomberg S, Dirschmid K, Hartmann BL, Knauer M, Drexel H, Wenzl E, De Vries A and Lang A: Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 21: 1283-1287, 2009.
24. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S and Bardelli A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712, 2008.